Diana Guerrero PATINO, Denis SINISTERRA, Jefferson Antonio BUENDIA

Cost of illness of RSV infection in a middle-income tropical country

Background. Despite the burden of disease of Respiratory syncytial virus (RSV) infection in children, there are important gaps in knowledge about the potential impact in terms of health as well as social and healthcare resources. The aim of this study was to describe the economic burden of RSV in the first two years of life in Colombia. Methods. We conducted a cost-of-illness study, taking a population prevalence-based approach. A decision tree model was constructed with a time horizon of two years. We defined the following outcomes: death, RSV infection with long term complications, RSV with acute complications, RSV without complications. Inpatient and outpatient costs were collected directly from medical invoices of patients who attended a tertiary referral hospital. Results. The mean cost per patient with an RSV infection was US$ 178.35 CI 95% (30.7-541.67 US$). The total cost of RSV infection in children less than 2 years in Colombia was US $ 64 443 616 per year (CI 95% US$11 092 902 – US$195 722 867). In the probabilistic sensitivity analysis, the mean cost per patient with RSV infection was only sensitive to changes in the cost of recurrent wheezing, cost of outpatient visits and cost of hospitalizations. Conclusion. The infection by RSV in Colombia generates a high economic burden on the health system. Generating comprehensive data on healthcare resource use and costs associated with RSV will help to provide valuable information for the development of cost-effectiveness models, and help guide prevention strategies against RSV.

PDF

___

1. Shi T, McAllister DA, O’Brien KL, et al; RSV Global Epidemiology Network.Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in young children in 2015: a systematic review and modelling study. Lancet 2017; 390: 946-958.

2. Nair H, Nokes DJ, Gessner BD, et al. Global burden of acute lower respiratory infections due to respiratory syncytial virus in young children: a systematic review and meta-analysis. Lancet 2010; 375: 1545-1555.

3. Drysdale SB, Sande CJ, Green CA, Pollard AJ. RSV vaccine use--the missing data. Expert Rev Vaccines 2016; 15: 149-152.

4. Zepeda TJ, Vasquez ZJ, Delpiano ML. Direct costs of low respiratory infection due to RSV in children under one year. Rev Chil Pediatr 2018; 89: 462-470.

5. Kramer R, Duclos A, Lina B, Casalegno JS; VRS study group in Lyon. Cost and burden of RSV related hospitalisation from 2012 to 2017 in the first year of life in Lyon, France. Vaccine 2018; 36: 6591-6593.

6. Mac S, Sumner A, Duchesne-Belanger S, Stirling R, Tunis M, Sander B. Cost-effectiveness of Palivizumab for Respiratory Syncytial Virus: a systematic review. Pediatrics 2019; 143: e20184064.

7. Paramore LC, Ciuryla V, Ciesla G, Liu L. Economic impact of respiratory syncytial virus-related illness in the US: an analysis of national databases. Pharmacoeconomics 2004; 22: 275-284.

8. Barbosa Ramirez J, Pulido Dominguez P, Rey Benito G, Mendez Rico J, Castellanos J, Páez Martinez A.Human respiratory syncytial virus and metapneumovirus in patients with acute respiratory infection in Colombia, 2000-2011. Rev Panam Salud Publica 2014; 36: 101-109.

9. Barton P, Bryan S, Robinson S. Modelling in the economic evaluation of health care: selecting the appropriate approach. J Health Serv Res Policy 2004; 9: 110-118.

10. Bereza BG, Machado M, Papadimitropoulos M, Sproule B, Ravindran AV, Einarson TR. A markov model approach assessing the cost of illness of generalized anxiety disorder in Canada. Neurol Ther 2012; 1: 1.

11. Shah NT, Wright KN, Jonsdottir GM, Jorgensen S, Einarsson JI, Muto MG. The feasibility of societal cost equivalence between robotic hysterectomy and alternate hysterectomy methods for endometrial cancer. Obstet Gynecol Int 2011; 2011: 570464.

12. Furiak N, Klein RW, Gahn JC, Camber SB, Summers K. Use of a decision tree model to estimate the economic benefits of reducing schizophrenia illness relapse. Value Health 2013; 16: A62-A63.

13. Barbosa J , Parra B, Alarcon L, Quinones FI, Lopez E, Franco MA. Prevalencia y periodicidad del virus sincitial respiratorio en Colombia. Rev Acad Colomb Cienc Ex Fis Nat 2017; 41: 435-446.

14. Cenco Nacional de Poblacion Y ViviendaCNPV-2018. Proyecciones de Poblacion.at: https:// www.dane.gov.co/index.php/estadisticas-por-tema/ demografia-y-poblacion/proyecciones-de-poblacion (Accessed on June 4, 2021).

15. Henderson J, Hilliard TN, Sherriff A, Stalker D, Al Shammari N, Thomas HM. Hospitalization for RSV bronchiolitis before 12 months of age and subsequent asthma, atopy and wheeze: a longitudinal birth cohort study. Pediatr Allergy Immunol 2005; 16: 386-392.

16. Ferolla FM, Hijano DR, Acosta PL, et al. Macronutrients during pregnancy and lifethreatening respiratory syncytial virus infections in children. Am J Respir Crit Care Med 2013; 187: 983- 990.

17. Colombia. Ministerio de Salud y Protección Social, Universidad de Antioquia. Guía de Práctica Clínica (GPC) Para la evaluación del riesgo y manejo inicial neumonía en niños y niñas menores de 5 años y bronquiolitis en niños y niñas menores de 2 años. Sistema General de Seguridad Social en Salud-Colombia. Para uso de profesionales de la salud 2014-Guía No.42 Available at: (PDF) Colombia. Ministerio de Salud y Protección Social, Universidad de Antioquia. Guía de práctica clínica para la evaluación del riesgo y manejo inicial de la neumonía en niños y niñas menores de 5 años y bronquiolitis en niños y niñas menores de 2 años. 2014 Guía No. 42. Guia completa (researchgate.net) (Accessed on June 4, 2021).

18. Briggs A, Gray A. The distribution of health care costs and their statistical analysis for economic evaluation. J Health Serv Res Policy 1998; 3: 233-245.

19. Pineros JG, Baquero H, Bastidas J, et al. Respiratory syncytial virus infection as a cause of hospitalization in population under 1 year in Colombia. J Pediatr (Rio J) 2013; 89: 544-548.

20. Ministerio de Salud y Protección Social. Gasto de Salud en Colombia 2018 Available from: https://www.minsalud.gov.co/proteccionsocial/ Financiamiento/Paginas/indicadores_generales. aspx.(Accessed on June 04, 2021).

21. Ministerio de Salud y Protección Social. Atenciones en Salud 2019.Available from: https://www.sispro. gov.co/central-gestion-del-conocimiento/Pages/ construya-su-consulta-afiliaciones-en-salud.aspx. (Accessed on May 20, 2019).

22. D Sinisterra, Buendía J. Cost illness of RSV infection in Colombia. Value Health 2017; 20: A923-A924.

23. Rodriguez-Martinez CE, Sossa-Briceno MP, CastroRodriguez JA.Direct medical costs of RSV-related bronchiolitis hospitalizations in a middle-income tropical country. Allergol Immunopathol (Madr) 2020; 48: 56-61.

24. Bhuiyan MU, Luby SP, Alamgir NI, et al. Costs of hospitalization with respiratory syncytial virus illness among children aged <5 years and the financial impact on households in Bangladesh, 2010. J Glob Health 2017; 7: 010412.

25. Zhang T, Zhu Q, Zhang X, et al. Clinical characteristics and direct medical cost of respiratory syncytial virus infection in children hospitalized in Suzhou, China. Pediatr Infect Dis J 2014; 33: 337-341.

26. Pelletier AJ, Mansbach JM, Camargo CA Jr. Direct medical costs of bronchiolitis hospitalizations in the United States. Pediatrics 2006; 118: 2418-2423.

27. Greenough A, Alexander J, Burgess S, et al. Health care utilisation of prematurely born, preschool children related to hospitalisation for RSV infection. Arch Dis Child 2004; 89: 673-678.

28. Heikkinen T, Ojala E, Waris M. Clinical and socioeconomic burden of respiratory syncytial virus infection in children. J Infect Dis 2017; 215: 17-23.

29. Amand C, Tong S, Kieffer A, Kyaw MH. Healthcare resource use and economic burden attributable to respiratory syncytial virus in the United States: a claims database analysis. BMC Health Serv Res 2018; 18: 294.